Loading...
NPI 1194214510 · Corinth, MS · Ambulatory Surgical Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Specialty Surgery & Laser Center is a ambulatory surgical clinic/center provider located in Corinth, Mississippi. This profile covers 14 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Specialty Surgery & Laser Center |
| Address | 306 Bradley Rd Ste A |
| City | Corinth |
| State | MS |
| ZIP | 38834 |
| Taxonomy | Ambulatory Surgical Clinic/Center |
| NPI Enumerated | May 2, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $261.4K |
SPECIALTY SURGERY & LASER CENTER’s code mix and taxonomy (Ambulatory Surgical Clinic/Center) identify it clearly as an ophthalmic-focused ambulatory surgery practice: the Medicare top codes are led by 66984 (cataract extraction with IOL), supported by ophthalmic drug codes J1096 (dexamethasone lacrimal insert) and J1097 (phenylephrine/ketorolac irrigation), indicating the center centers its volume on cataract procedures with concurrent intraocular pharmacologic management. The presence of additional procedure codes such as 66991, 15823, 66174 and 65855 shows the ASC also performs related glaucoma and oculoplastic procedures, consistent with a specialty cataract and anterior-segment surgical practice.
Revenue is highly concentrated by a few codes for both payers: the precomputed top three Medicare codes account for 75.8% of this provider’s total Medicare revenue, and the precomputed top three Medicaid codes make up 100.0% of its Medicaid revenue. That concentration signals the business is heavily dependent on a narrow set of cataract and intraocular-drug services for its payer receipts.
On payer mix, Medicare dominates this provider’s recorded lifetime revenue: total Medicare revenue is $1.9M versus total Medicaid revenue of $261.4K, making Medicare the primary commercial driver for the practice’s lifetime billing. Medicaid is present but materially smaller in scale, so changes in Medicare reimbursement or utilization would have outsized effects on overall revenue.
Competitive standing for the primary Medicare cataract code 66984 is nationally solid but not exceptional: 66984 generates $805.2K (41.6% of Medicare revenue) and ranks #1883 of 15965 providers nationally (88th percentile), characterized in the data as typical/unremarkable volume for this code. By contrast, J1096 is a clear outlier on Medicare: it produces $395.2K (20.4% of Medicare revenue) and ranks #16 of 282 providers nationally (95th percentile), explicitly noted as notably above typical national volume and suggesting the center is a major user of intraocular dexamethasone inserts relative to peers.
In-state (Medicaid) competitive positioning is concentrated in cataract procedures: Medicaid billing for 66984 accounts for $258.9K (98.9% of Medicaid revenue) and ranks #12 of 42 providers in-state (73rd percentile), indicating a moderate presence within Mississippi among Medicaid-performing sites. Medicaid reporting for J1096 shows much smaller Medicaid revenue ($2.8K, 1.1% of Medicaid revenue) but ranks #1 of 2 providers in-state (100th percentile), a high rank that reflects a very small comparator pool rather than broad statewide dominance.
The dataset contains notable utilization patterns and reporting oddities worth flagging: on Medicare, J2403 appears as 87.2K claims for $87.2K revenue (4.5% of Medicare revenue) yet ranks #41 of 76 providers nationally (47th percentile), which reads as a high absolute claims count but only a middling position within a very small peer set. On Medicaid, some codes (for example J1095 and J1097) show claims but $0 revenue reported, indicating either zero paid claims for those codes in Medicaid data or data-recording nuances that would merit follow-up before operational conclusions are drawn.
Tenure and operational maturity are straightforward: the NPI was enumerated on 2018-05-02 (~8 years ago), so the center has multiple years of billing history but is not a long-established multi-decade provider. That tenure, combined with concentrated code reliance, suggests a relatively recent but focused ASC operation that has specialized quickly in high-volume cataract and intraocular pharmacologic services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 1,100 | $730 | $805.2K |
| J1096 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg | 3,990 | $100 | $395.2K |
| J1097 | phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | 3,520 | $80 | $267.2K |
| 66991 | The provider inserts an intraocular lens prosthesis during the same session as extracapsular cataract extraction. The provider also inserts one or more anterior segment aqueous drainage devices in… | 70 | $2,170 | $141.1K |
| J2403 | Chloroprocaine hcl ophthalmic, 3% gel, 1 mg | 87,200 | $1 | $87.2K |
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram | 270 | $160 | $43.7K |
| 15823 | In this procedure, the provider surgically trims excessive skin that weighs down the upper eyelid, typically to improve the cosmetic appearance of the face and due to the interference of the tissue… | 100 | $400 | $40.3K |
| 66174 | The provider expands the aqueous outflow (drainage) canal of the eye to help relieve pressure in the eye. The procedure does not include leaving a device or stent in place. | 50 | $710 | $34.5K |
| 66821 | The provider removes the haziness from the capsule of the eye using a laser for a patient with a secondary membranous cataract. | 200 | $170 | $33.6K |
| 65820 | The provider incises the limbus to improve drainage of aqueous humor in the eye. This procedure is typically performed on children, usually to treat congenital glaucoma. | 50 | $660 | $32.5K |
Showing 1–10 of 14
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
14 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J1097 | 5 | 10 | 3,040 | $80 | $244.1K |
| J1096 | 1 | 10 | 840 | $100 | $150.6K |
| J2403 | 2 | 10 | 193,600 | $1 | $108.2K |
| 66984 | 5 | 240 | 70 | $470 | $90.5K |
| J7351 | 3 | 10 | 360 | $160 | $76.6K |
| 66991 | 6 | 20 | 40 | $1,300 | $62.6K |
| 67904 | 13 | 20 | 80 | $520 | $39K |
| 65820 | 6 | 20 | 30 | $790 | $35.3K |
| 66174 | 5 | 10 | 50 | $680 | $29.2K |
| 15823 | 6 | 40 | 40 | $460 | $25.2K |
Showing 1–10 of 14
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 1,230 | $210 | $258.9K |
| J1096 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg | 160 | $20 | $2.8K |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 110 | $1 | $210 |
| J1095 | Injection, dexamethasone 9 percent, intraocular, 1 microgram | 30 | $0 | $0 |
| J1097 | phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 66984 | The provider inserts an artificial lens after removing an extracapsular cataract by aspiration or use of ultrasonic waves. This procedure is done without the use of an endoscopic laser probe to… | 12 | 40 | 300 | $180 | $191.9K |
| J1097 | phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | 10 | 10 | 190 | $20 | $12.9K |
| J1096 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg | 1 | 10 | 120 | $30 | $3.9K |
| J1095 | Injection, dexamethasone 9 percent, intraocular, 1 microgram | 2 | 10 | 130 | $10 | $850 |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 46 | 60 | 520 | $1 | $200 |
Other providers in the same ZIP code as Specialty Surgery & Laser Center, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.